Ocugen Inc (OCGN)

Apr 16, 2025

Is Ocugen Inc. (NASDAQ:OCGN) the Best Penny Stock to Invest in Under $1? - Insider Monkey

Apr 16, 2025

Apr 09, 2025

Ocugen CEO to Present at Prestigious Cell & Gene Meeting on the Mediterranean - MyChesCo

Apr 09, 2025

Apr 08, 2025

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med - Ocugen

Apr 08, 2025

Apr 01, 2025

Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch

Apr 01, 2025

Mar 30, 2025

OCGN Stock Forecast: 2025-2035 Predictions - Exla Resources

Mar 30, 2025

Mar 26, 2025

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Yahoo Finance

Mar 26, 2025

Mar 22, 2025

Ocugen Advances OCU200 Clinical Trial Amid Promising Safety Results - MSN

Mar 22, 2025

Mar 20, 2025

Stock Quote & Chart - Ocugen

Mar 20, 2025

Mar 19, 2025

Ocugen receives DSMB approval to continue dosing in Phase I trial of OCU200 - Yahoo

Mar 19, 2025

Mar 19, 2025

Ocugen’s OCU200 advances to next trial phase with safety approval By Investing.com - Investing.com Australia

Mar 19, 2025

Mar 19, 2025

ROSEN, A LEADING LAW FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important August 17 Deadline in Securities Class Action – OCGN - Business Wire

Mar 19, 2025

Mar 18, 2025

OCGN stock touches 52-week low at $0.52 amid market challenges By Investing.com - Investing.com South Africa

Mar 18, 2025

Mar 18, 2025

OCGN stock touches 52-week low at $0.52 amid market challenges - Investing.com India

Mar 18, 2025

Mar 18, 2025

Ocugen Advances OCU200 Trial After Safety Board Review -March 18, 2025 at 08:31 am EDT - Marketscreener.com

Mar 18, 2025

Mar 18, 2025

Ocugen says DSMB approves dosing Cohort 2 in OCU200 clinical trial - TipRanks

Mar 18, 2025

Mar 18, 2025

Ocugen’s OCU200 advances to next trial phase with safety approval - Investing.com India

Mar 18, 2025

Mar 18, 2025

Ocugen Announces Approval to Continue Dosing in Phase 1 Trial of OCU200 Following Favorable Safety Review - Nasdaq

Mar 18, 2025

Mar 18, 2025

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema - Ocugen

Mar 18, 2025

Mar 18, 2025

Data and Safety Monitoring Board Reviews Cohort 1 Safety - GlobeNewswire

Mar 18, 2025

Mar 18, 2025

Breakthrough Eye Treatment Passes Critical Safety Review: What This Means for 130M Patients - Stock Titan

Mar 18, 2025

Mar 17, 2025

Ocugen seeks its One Shining Moment - The Healthcare Technology Report.

Mar 17, 2025

Mar 17, 2025

Breakthrough in Sight? Ocugen’s OCU200 Targets Vision Loss for Millions in New Clinical Trial - MSN

Mar 17, 2025

Mar 12, 2025

Ocugen Inc. Navigates Uncertainty Amid Potential Shifts in U.S. Fiscal and Tax Policies - MSN

Mar 12, 2025

Mar 12, 2025

SBI Securities Co. Ltd. Makes New $40,000 Investment in Ocugen, Inc. (NASDAQ:OCGN) - Defense World

Mar 12, 2025

Mar 10, 2025

Ocugen, Inc. (NASDAQ:OCGN) Shares Acquired by Rhumbline Advisers - Defense World

Mar 10, 2025

Mar 10, 2025

Equities Analysts Offer Predictions for Ocugen Q1 Earnings - Defense World

Mar 10, 2025

Mar 09, 2025

FY2029 Earnings Estimate for Ocugen Issued By HC Wainwright - Defense World

Mar 09, 2025

Mar 09, 2025

Ocugen’s (OCGN) “Buy” Rating Reiterated at HC Wainwright - Defense World

Mar 09, 2025

Mar 08, 2025

Ocugen Secures ATMP Classification for Gene Therapies Targeting Vision Loss - MSN

Mar 08, 2025

Mar 07, 2025

Ocugen Stock Lifts Retail Investor Confidence As Q4 Revenue Crushes Estimates - MSN

Mar 07, 2025

Mar 07, 2025

Ocugen’s Strategic Advancements and Financial Stability Justify Buy Rating - TipRanks

Mar 07, 2025

Mar 07, 2025

Ocugen Reports 2024 Financial Results and Advances Gene Therapy Programs - MSN

Mar 07, 2025

Mar 06, 2025

Attention Long-Term Shareholders of Driven Brands Holdings, - GlobeNewswire

Mar 06, 2025

Mar 06, 2025

Attention Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); MGP Ingredients, Inc. (NASDAQ: MGPI); and Ocugen, Inc. (NASDAQ: OCGN): Grabar Law Office Investigates Claims on Your Behalf - GlobeNewswire Inc.

Mar 06, 2025

Mar 06, 2025

Chardan Capital Adjusts Ocugen Price Target to $7 From $6, Maintains Buy Rating -March 06, 2025 at 08:15 am EST - Marketscreener.com

Mar 06, 2025

Mar 06, 2025

Ocugen, Inc. (NASDAQ:OCGN) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 06, 2025

Mar 06, 2025

Ocugen’s Strategic BLA Submissions and Financial Position Support Buy Rating - TipRanks

Mar 06, 2025

Mar 06, 2025

Beyond The Numbers: 5 Analysts Discuss Ocugen StockOcugen (NASDAQ:OCGN) - Benzinga

Mar 06, 2025

Mar 06, 2025

Y Intercept Hong Kong Ltd Makes New Investment in Ocugen, Inc. (NASDAQ:OCGN) - Defense World

Mar 06, 2025

Mar 06, 2025

Ocugen: Q4 Earnings Snapshot - Midland Daily News

Mar 06, 2025

Mar 06, 2025

Ocugen Inc (OCGN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs - Yahoo Finance

Mar 06, 2025

Mar 05, 2025

Ocugen Reports Progress in Gene Therapy Trials - TipRanks

Mar 05, 2025

Mar 05, 2025

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire

Mar 05, 2025

Mar 05, 2025

Ocugen Inc Earnings Call: Strategic Gains Amid Financial Challenges - TipRanks

Mar 05, 2025

Mar 05, 2025

Around the Helix: Cell and Gene Therapy Company Updates – March 5, 2025 - CGTLive™

Mar 05, 2025

Mar 05, 2025

Ocugen Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 05, 2025

Mar 05, 2025

Ocugen (OCGN) Q4 2024 Earnings Call Transcript - Yahoo

Mar 05, 2025